7:18 PM
 | 
Apr 14, 2015
 |  BC Extra  |  Company News

Lummy gains Chinese rights to Argos' AGS-003

Argos Therapeutics Inc. (NASDAQ:ARGS) granted the Lummy Co. Ltd. subsidiary of Chongqing Lummy Pharmaceutical Co. Ltd. (SZSE:300006) development and commercialization rights in greater China for AGS-003 in oncology indications.

Argos is conducting a Phase III study of the second-generation RNA-loaded autologous dendritic cell immunotherapy to treat metastatic renal cell carcinoma (mRCC). Lummy said it...

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >